Drug Database
TR

triamcinolone acetonide (Azmacort 134a / KI03216 / Azmacort CFC)

✓ Approved

AbbVie, Inc. · NR3C1 · 小分子

什么是 triamcinolone acetonide?

triamcinolone acetonide 是一种小分子,由AbbVie, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Inhaled、Topical。

药物档案

商品名Azmacort 134a, KI03216, Azmacort CFC
公司AbbVie, Inc.
药物类别小分子
分子靶点NR3C1
给药途径Inhaled, Topical
状态Approved

作用机制

分子靶点

triamcinolone acetonide 作用于 1 个分子靶点:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

triamcinolone acetonide 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved

相关研究文献

PubMedThe Journal of dermatological treatment2026-11-20

Intralesional triamcinolone plus gentamicin versus triamcinolone alone for keloid: a two-center cohort study.

Park Joseph Kyu-Hyung JK, Choi Nakwon N, Kim Jong-Ho JH, Kim Baek-Kyu BK et al.

Keloid recurrence remains common after intralesional triamcinolone acetonide (TAC), the first-line therapy, and microbial colonization of the deep dermis has been implicated in keloid pathobiology; however, TAC combined with an antimicrobial has not been tested in a controlled comparison. We conducted a two-center retrospective cohort study comparing intralesional TAC plus gentamicin with TAC alone in adults with keloid. The primary outcome was change in the Vancouver Scar Scale (VSS) from baseline to a standardized 12-month post-treatment assessment, scored independently by two blinded plastic surgeons (ICC 0.90) and analyzed by baseline-adjusted analysis of covariance; a paired survey cohort (n = 109) provided recurrence and symptom outcomes. Among 48 patients (24 per group), VSS reduction was threefold greater with TAC plus gentamicin than with TAC alone (-3.00 vs -1.04; adjusted β = -2.00; 95% confidence interval [CI], -2.86 to -1.14; p < 0.001; Cohen d = 1.27), and 29% versus 0% achieved at least 50% reduction. The effect persisted after adjusting for session number and follow-up (E-value, 5.8). The survey cohort reported a higher recurrence-free proportion, longer time to recurrence, and faster symptom relief. Adding gentamicin to intralesional TAC was associated with greater scar improvement, but treatment was confounded with site of care; randomized confirmation is required before clinical adoption.

PMID 43059261
阅读全文 →
PubMedOral diseases2026-11-19

Variation in Basal Serum Cortisol Levels During Treatment of Oral Lichen Planus With 0.5% Triamcinolone Acetonide Mouthrinses: A Prospective Observational Study.

Blanco-Aguilera Elena E, Gándara-Vila Pilar P, Sanmartín-Barragáns Valeria V, Rodríguez-García Javier J et al.

To evaluate changes in basal serum cortisol levels in patients with atrophic-erosive oral lichen planus (OLP) and oral lichenoid lesion (OLL) treated with 0.5% triamcinolone acetonide mouthrinses and to assess the occurrence of clinical manifestations associated with adrenal dysfunction. A prospective observational study was conducted in 68 patients with clinically and histopathologically confirmed atrophic-erosive OLP or OLL. Participants received 0.5% triamcinolone acetonide mouthrinses following a tapering regimen over 3 months. Basal serum cortisol levels were measured at baseline, after 30 days, and after 90 days of treatment. Clinical and demographic variables and treatment-related adverse effects were analyzed. Mean basal serum cortisol levels decreased from 17.05 ± 4.38 μg/dL at baseline to 8.79 ± 7.34 μg/dL after 1 month of treatment. Following dose tapering, serum cortisol levels (SCL) partially recovered to 11.94 ± 6.44 μg/dL at 3 months. No clinical manifestations of adrenal insufficiency were observed. Baseline SCL were significantly associated with serum cortisol concentrations after 1 month (r = 0.34; p < 0.05). Older patients exhibited smaller hormonal fluctuations during treatment. Triamcinolone acetonide induced a transient reduction in SCL without clinically relevant adrenal dysfunction, suggesting a limited systemic impact when administered a tapering regimen.

PMID 43053526
阅读全文 →
PubMedThe Journal of clinical and aesthetic dermatology2026-11-19

Suspected Pityriasis Rubra Pilaris-Like Eruption Following SGLT2 Inhibitor Therapy: A Case Report.

Frederickson Katie L KL, Ehimwenma-Point Du Jour Tammy E TE, Pourali Sarah P SP, Nzerue Chike C

This case report represents a 62-year-old African American female patient with diabetic kidney disease who presented with a suspected pityriasis rubra pilaris-like eruption after starting oral empagliflozin for 1 week. The patient presented with a severely pruritic rash, erythematous plaques, hyperpigmented patches, and follicular papules on the scalp, face, trunk, and extremities. The patient did not respond to initial treatment including topical mometasone or oral prednisone. Gabapentin, topical triamcinolone, clobetasol, and tacrolimus were additionally prescribed for symptomatic relief. Acitretin was initiated and slowly titrated from 10 to 25 to 30 mg daily. Aprelimast was added at the 6-month follow-up to further increase clearance. Slow yet progressive improvement of the rash and pruritus was observed. This clinical vignette highlights the importance of early clinical recognition and education about the adverse effects of temporally associated empagliflozin pityriasis rubra pilaris-like eruptions.

PMID 43054795
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Evaluation of Intralesional Triamcinolone Acetonide and Platelet-Rich Plasma Therapy in Patients With Mild Patch-Type Alopecia Areata.

Ülker Ramazan R, Özdemir İlknur Yorğun İY, Özkol Hatice Uce HU

Alopecia areata is a long-term autoimmune disease that causes hair loss in approximately 2% of people but does not result in permanent scarring. Intralesional corticosteroid treatment provides effective results; however, long-term use may lead to skin atrophy and telangiectasia. Platelet-rich plasma (PRP), an autologous blood-derived preparation, represents a patient-specific alternative that avoids steroid-related side effects. To compare the efficacy and safety of intralesional PRP and intralesional triamcinolone acetonide (ILTA) in patients with mild patch-type (S1) alopecia areata. This prospective study included patients aged 18-65 years with mild patch-type alopecia areata who were admitted to our clinic between March 2024 and March 2025 and had not received any previous treatment. Patients were allocated into two groups; both groups received a total of three sessions of treatment every 4 weeks. The primary endpoint was the change in SALT score from baseline to the 6th month. Secondary endpoints included the change in SALT score at the 3rd month, clinical response categories, hair pull test conversion, relapse rate during 6-month follow-up, and the adverse-event profile. SALT scores were calculated at baseline, 3 months, and 6 months. Sixty patients (41 males, 19 females; mean age 27.97 ± 7.36 years) completed the study. SALT scores decreased significantly in both groups (p < 0.001). The score decreased from 6.03 to 0.93 in the PRP group and from 6.07 to 1.27 in the ILTA group, with no statistically significant difference between groups (mean difference 0.30; 95% CI -0.77 to 1.37; p = 0.576). The very good response rate (≥ 75% improvement) at six months was 76.67% in the PRP group and 66.67% in the ILTA group. Relapse occurred in 3 of 60 patients (5.0%) during the 6-month follow-up (1/30 (3.33%) in the PRP group and 2/30 (6.67%) in the ILTA group). Both groups experienced only mild adverse events; no serious side effects were observed. In mild untreated patch-type alopecia areata, PRP showed similar efficacy to intralesional triamcinolone acetonide and may be considered an alternative treatment option for mild patch-type alopecia areata.

PMID 43047042
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Efficacy of Laser-Assisted Intralesional Triamcinolone for Pathological Scars: A Systematic Review and Meta-Analysis.

Almutawaa Bader N BN, Almahzoum Kholoud K, Albannai Noof N, Alsuwailem Faisal Fahad FF et al.

Pathological scars result from aberrant wound healing and remain challenging to treat. Intralesional triamcinolone acetonide is the current mainstay of therapy. Recently, adjuvant laser therapy has emerged as a promising strategy to enhance drug penetration and modulate scar vasculature and collagen remodeling. This meta-analysis assesses the clinical efficacy of laser-assisted intralesional triamcinolone in the treatment of pathological scars. In March 2026, we conducted a systematic search of PubMed, Scopus, Web of Science, Embase, and the Cochrane Library for randomized controlled trials (RCTs) and non-randomized studies directly assessing laser plus intralesional triamcinolone. For the meta-analysis, we used R 4.5.0 with R Studio 2024.12.1 + 563. Our review included five RCTs and three non-randomized comparative studies. Six studies encompassing 248 patients were included in the meta-analysis. Compared with intralesional triamcinolone alone, laser combination therapy showed no significant difference in VSS/mVSS reduction (SMD = 0.28, 95% CI: -0.53 to 1.10, p = 0.496), with substantial heterogeneity (I2 = 83.1%). However, when compared with laser monotherapy, the combination significantly improved VSS/mVSS (SMD = -1.16, 95% CI: -1.85 to -0.48, p = 0.0008; I2 = 16.9%). Patient satisfaction appeared higher with combination therapy, but certainty was low, and the comparison with laser monotherapy was based on a single study. For VSS subscales vs. laser alone, combination therapy significantly improved vascularity, pliability, and height, but not pigmentation. Recurrence rates did not differ significantly between groups. Laser plus intralesional triamcinolone may improve scar scores and patient satisfaction compared with laser monotherapy, but current evidence does not demonstrate superiority over intralesional triamcinolone alone. Recurrence benefit remains uncertain. However, our findings are limited by the small number of RCTs and substantial heterogeneity. Future adequately powered RCTs with longer follow-up periods are warranted.

PMID 43047260
阅读全文 →
PubMedJFMS open reports2026-11-18

Use of subconjunctival cyclosporine implants for treatment of feline eosinophilic keratoconjunctivitis: A case report.

Willems Lynn L, Roberts Jordan K JK

A 5-year-old, neutered male domestic shorthair cat was presented for evaluation of chronic bilateral eosinophilic keratoconjunctivitis (EK). The patient had a history of recurrent corneal plaques and conjunctivitis that were initially managed with systemic and topical immunosuppressive therapy. Long-term disease control was limited by poor tolerance of topical ophthalmic medications, resulting in inconsistent treatment and repeated disease recurrence affecting both eyes. Over several years, the cat was treated with subconjunctival triamcinolone acetonide, antiviral therapy, and topical megestrol acetate, with only partial and temporary improvement. As a result of persistent disease and inability to administer long-term topical therapy reliably, bilateral subconjunctival cyclosporine implants were surgically placed. Postoperative management included short-term topical antibiotic therapy. At 10-week and 7-month postoperative examinations, marked clinical improvement was observed, with resolution of most corneal plaques and substantial reduction in conjunctival inflammation. Feline EK is a chronic immune-mediated ocular surface disease that typically requires long-term topical immunosuppressive therapy. Successful management may be limited in patients who are resistant to medication administration. This case demonstrates that subconjunctival cyclosporine implants may represent a viable long-acting treatment option for feline EK when topical therapy cannot be consistently administered. To the authors' knowledge, the use of cyclosporine implants for the management of feline EK has not previously been reported.

PMID 43048052
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多triamcinolone acetonide